Strides Pharma Science announced its consolidated financial results for the quarter (Q2FY26) and half year (H1FY26) ended September 30, 2025.

The company registered a revenue at Rs 12,208 million, grew 4.6 per cent YoY, absolute gross margin at Rs 7,056 million, grew 14.6 per cent YoY, gross margin improved to 57.8 per cent, up 500 bps YoY, EBITDA grew 25.4 per cent YoY to Rs 2,316 million, EBITDA margin at 19 million, grew 320bps YoY, other regulated markets revenue at $44 million, delivered strong growth of 16 per cent YoY, operational PAT at Rs 1,403 million, grew 84.3 per cent YoY, operational EPS at Rs 15.2, reported PAT at Rs 1,315 million.

Badree Komandur, MD and Group CEO, Strides Pharma Science said, “Strides continues to deliver a strong performance in Q2FY26, with growth primarily driven by the Other Regulated Markets. Our focus on profitability enabled the gross margin growth of 15 per cent YoY, and EBITDA growth of 25 per cent YoY. Operational PAT stood at Rs 1,403 million, up 84 per cent YoY, with EPS rising to Rs 15.2 for the quarter. Net debt reduced sequentially by Rs 469 million despite currency headwinds and ongoing capex investments, reaffirming our strong financial discipline and focus on balance sheet health. This performance demonstrates our consistent execution as we continue to invest in sustainable, long-term growth.”